Logo

IOVA

Iovance Biotherapeutics, Inc.

IOVA

Iovance Biotherapeutics, Inc. • NASDAQ
$2.47 ▲ 1.23% (+0.03)
Market Cap $819.27 M
52w High $9.38
52w Low $1.64
Dividend Yield 0%
P/E -2.08
Volume 2.49M
Outstanding Shares 331.69M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $67.455M ▲ $160.948M ▲ $-91.253M ▲ -135.28% ▲ $-0.25 ▲ $-84.651M ▲
Q2-2025 $59.952M ▲ $117.062M ▼ $-111.658M ▲ -186.246% ▲ $-0.33 ▲ $-101.836M ▲
Q1-2025 $49.324M ▼ $120.804M ▲ $-116.163M ▼ -235.51% ▼ $-0.36 ▼ $-106.936M ▼
Q4-2024 $73.694M ▲ $114.727M ▲ $-78.559M ▲ -106.602% ▲ $-0.26 ▲ $-74.889M ▲
Q3-2024 $58.554M $107.797M $-83.541M -142.673% $-0.28 $-77.919M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $300.803M ▼ $904.948M ▼ $202.661M ▼ $702.287M ▲
Q2-2025 $301.183M ▼ $907.437M ▼ $208.949M ▲ $698.488M ▼
Q1-2025 $359.713M ▲ $966.74M ▲ $198.875M ▼ $767.865M ▲
Q4-2024 $323.781M ▼ $910.426M ▼ $200.021M ▼ $710.405M ▼
Q3-2024 $397.488M $991.115M $217.66M $773.455M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-91.253M ▲ $-78.702M ▼ $17.012M ▲ $88.056M ▲ $25.665M ▲ $-89.546M ▼
Q2-2025 $-111.658M ▲ $-67.447M ▲ $13.842M ▼ $13.23M ▼ $-39.636M ▼ $-74.908M ▲
Q1-2025 $-116.163M ▼ $-103.694M ▼ $15.867M ▼ $143.315M ▲ $55.996M ▲ $-109.905M ▼
Q4-2024 $-78.559M ▲ $-73.296M ▼ $23.677M ▲ $2.309M ▼ $-48.492M ▲ $-77.464M ▼
Q3-2024 $-83.541M $-58.973M $-48.801M $41.954M $-64.567M $-61.261M

Five-Year Company Overview

Income Statement

Income Statement Iovance is still very much in the investment phase. Revenue has only just begun to appear and is still tiny compared with its spending. The company has posted sizable operating and net losses every year, reflecting heavy research, clinical, and now commercialization costs. Losses widened through 2022 and then began to improve slightly, but the path to break-even still depends heavily on how quickly product sales ramp and how well operating costs are controlled. Overall, the income statement shows a company transitioning from pure R&D to early commercialization, but not yet close to profitability.

Balance Sheet

Balance Sheet The balance sheet shows a typical profile for a development‑stage biotech that has built substantial infrastructure. Total assets have grown over time, supported mainly by equity funding rather than heavy borrowing. Cash and investments form a meaningful portion of assets, though not large relative to ongoing cash burn. Debt exists but appears modest compared with total assets and equity, suggesting financial leverage is not extreme. Shareholders’ equity remains positive, indicating a cushion, but continued losses will steadily erode that unless offset by new capital or a successful commercial ramp.

Cash Flow

Cash Flow Cash flows are clearly negative. The company has consistently used cash in its core operations, with outflows rising during peak investment periods. Free cash flow is also firmly negative, meaning that even after capital spending, the business consumes rather than generates cash. Capital expenditures have eased a bit after prior investment in manufacturing capacity, but operating cash burn remains the main driver. Management’s recent cost-cutting steps are aimed at stretching the existing cash balance, yet the long-term sustainability of cash flow will depend on how quickly product revenue can grow and whether additional funding is needed if commercialization takes longer than expected.

Competitive Edge

Competitive Edge Iovance holds a differentiated position within oncology by focusing on tumor‑infiltrating lymphocyte (TIL) therapy for solid tumors, an area with fewer direct competitors than blood cancer cell therapies. Its first‑mover status, extensive patent portfolio, and large dedicated manufacturing facility give it meaningful advantages and create barriers for new entrants. At the same time, it competes in a very crowded cancer market that includes big pharmaceutical companies, multiple immunotherapy approaches, and constant innovation. The real test of its competitive position will be commercial execution: proving that physicians adopt its therapy, payers support it, and manufacturing remains reliable at scale.

Innovation and R&D

Innovation and R&D Innovation is clearly Iovance’s core strength. The company has built an end‑to‑end TIL platform, including a large, specialized cell therapy center and sophisticated processes for turning a patient’s own immune cells into a treatment. It is also pushing into next‑generation products, such as gene‑edited TILs and an improved IL‑2 analog, aimed at making treatments more effective and durable. The depth of the patent estate and focus on hard‑to‑treat solid tumors highlight a strong scientific edge. However, these programs carry typical biotech risks: clinical setbacks, regulatory uncertainty, and the challenge of translating complex science into reliable, cost‑effective commercial products.

Summary

Overall, Iovance looks like a high‑innovation, high‑risk biotechnology company moving from development to early commercialization. Financially, it is still loss‑making with steady cash burn, supported by a balance sheet that currently has some cushion but will be sensitive to how quickly sales scale. Strategically, it has a distinctive niche in TIL therapy, supported by intellectual property, specialized manufacturing, and a focused pipeline targeting solid tumors. The company’s future will hinge on successful uptake and expansion of its lead product, continued progress in its pipeline, and its ability to manage costs and funding needs in a highly competitive and uncertain biotech landscape.

NEWS

November 21, 2025 · 5:15 PM UTC

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Read more

October 29, 2025 · 8:15 AM UTC

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Read more

October 17, 2025 · 5:15 PM UTC

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Read more

October 8, 2025 · 3:05 PM UTC

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Read more

September 19, 2025 · 5:00 PM UTC

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Read more